



## Integrium Awarded Two Hypertension Studies by a Major Pharmaceutical Company

TUSTIN, CA, October 11, 2006 – Integrium, a leading contract research organization (CRO) in the cardiovascular and metabolic areas, today announced that the company was awarded workscopes for two large hypertension studies by a major pharmaceutical company. This follows a number of trial workscopes previously managed by Integrium for this client.

These two Phase 4 trials involve hypertensive patients with Type 2 diabetes and elderly hypertensive patients, respectively. The trials will investigate the reduction in blood pressure, as measured by ambulatory blood pressure monitoring (ABPM). It is anticipated that each study will enroll 200 patients at 25 investigator sites in the US – utilizing Integrium’s detailed investigator database to identify and recruit these sites.

Integrium is providing a comprehensive range of services for the trial projects. This includes project management, site monitoring, data management, medical monitoring, site recruitment and contracting, vendor management, and regulatory services. Integrium will also be providing centralized ambulatory blood pressure monitoring (ABPM) services for both studies through its Integrex group.

“We welcome the opportunity to execute the clinical trial workscopes for these two important cardiovascular studies,” said David Smith, MD, Chief Medical Officer of Integrium. “Integrium will provide our client with a well-profiled network of investigator sites with cardiovascular trial experience which are capable of rapidly enrolling these two studies, as well as our operational capabilities and clinical expertise in the hypertension area.”

Integrium is a premier full-service contract research organization (CRO) for clinical trials in the cardiovascular and metabolic areas. The company provides biopharmaceutical clients with strong operational capabilities and in-depth clinical expertise in support of cardiovascular and metabolic development programs. Integrium was founded by three physician researchers in 1998 and supports trials on a domestic and multinational basis. Please visit [www.integrium.com](http://www.integrium.com) for more information.

### Contact

Richard Caroddo

Director, Business Development

(office) 212.584.9190 x222

(cell) 516.410.3884

[Richard.caroddo@integrium.com](mailto:Richard.caroddo@integrium.com)